1. Home
  2. BRW vs MGTX Comparison

BRW vs MGTX Comparison

Compare BRW & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRW

Saba Capital Income & Opportunities Fund SBI

HOLD

Current Price

$6.50

Market Cap

280.9M

Sector

Finance

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$11.32

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRW
MGTX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
909.1M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
BRW
MGTX
Price
$6.50
$11.32
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
237.7K
658.0K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
144.57
52 Week Low
$6.38
$6.31
52 Week High
$8.49
$11.85

Technical Indicators

Market Signals
Indicator
BRW
MGTX
Relative Strength Index (RSI) 36.88 68.97
Support Level $6.40 $7.11
Resistance Level $6.93 $11.85
Average True Range (ATR) 0.09 0.60
MACD -0.02 0.15
Stochastic Oscillator 0.00 85.11

Price Performance

Historical Comparison
BRW
MGTX

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: